Introduction
Introduction

Oncogenes and tumour suppressor genes regulate the growth and development of normal cells. Mutations and aberrant expression of these genes have been observed in a variety of human cancers
. Cancer cells are characterized by their ability to escape senescence, which is a form of programmed growth arrest that limits the replicative potential of most somatic cells and also functions as a mechanism of tumour suppression [3] [4] [5] . The senescent cells typically have flattened shape and large cytoplasmic vacuoles [6] , and can be distinguished histologically by staining with a chromogenic substrate for ␤-galactosidase [7] .
A number of genes that induce replicative senescence in human cancer cell lines have been successfully mapped by chromosome transfer experiments [8] [9] [10] . Chromosome 6 from normal human diploid cells, when transferred into tumour cells and SV40 immortalized cells, was shown to confer senescence on the recipient cells [11, 12] . Moreover, immortal revertants of the senescent clones were found to have consensus deletions in four specific regions of the donor chromosome 6 6PL) , an evolutionarily conserved ribonuclease that has also been identified as a candidate tumour suppressor gene by two other groups using different approaches [13, 14] . RNaseT2 homologues were recognized as regulatory proteins in plants [15] and their presence was subsequently confirmed in bacteria [16] , viruses [17] , Drosophila [18] and human beings [19] .
(R.S. Athwal, unpublished observations). The characterization of one of these regions indicated the deletion of RNaseT2 (formerly known as RNase
The full-length human RNaseT2 has 256 amino acids and a predicted size of 29 kD. The gene has nine exons that show differential splicing variants in some cDNA isolates [14] . The levels of RNaseT2 were found to be significantly reduced in ovarian carcinoma cell lines, but no mutations in this gene were found [13] . While the pRPc and SG10G cells transfected with RNaseT2 retained the parental phenotype, HEY4 and XP12RSOV transfectants acquired a senescent phenotype [13] . Subsequent studies confirmed that the human protein is a catalectically active RNase [20] , although it was reported that abolition of its catalytic activity did not alter its effect on tumorigenesis or metastasis [21] . Campomenosi et al . [20] showed that the full-length RNaseT2 is a secreted protein, although its proteolytic fragments remain in lysosomes. The (Fig. 1B) . (Fig. 2A) [14] (Fig. 3B) . Fig. 4A  and B) . In situ visualization of the tagged RNaseT2, by immunofluorescence, showed uniform distribution throughout the cytoplasm with a lesser signal associated with the nucleus (Fig. 4C) (Fig. 5A) , the growth of CSG2/RNaseT2 clones was reduced dramatically (Fig. 5B) (Fig. 6, parts A and B (Fig. 7) . Thus the colony forming efficiency and the ability to grow in soft agar of RNaseT2 expressing clones was significantly reduced relative to the controls. 
Materials and methods
Cell lines and culture conditions
Semi-quantitative RT-PCR
Sequences of primers
Alternative splicing of RNaseT2 transcript
or any other splice variants in nine cell lines that we tested (data not shown). It warrants mention that the splicing pattern observed for CRL-9609 and CSG2 cells were identical to the other SV40 immortalized cell lines AR5 and GM0487 (data not shown). We note that these primer pairs cannot detect splice variants that lack exon 4 or are much longer or much less abundant than the predominant isoform.
RNaseT2 expression in early and late passage cells
A semi-quantitative RT-PCR comparison of RNaseT2 expression in young (passage 2) and aged (passage 64) FS-2 cells, using primer pair F180/R588, revealed a significantly higher level in late passage cells relative to early passage cells (Fig. 3A). The cDNA product of mRNA from aged cells was visible after 18 cycles of amplification, but it was detectable only after 26 cycles in young cells. A densitometric analysis of the amplified products of GAPDH and RNaseT2 transcripts confirmed the quantitative changes in early and late passage cells at different cycles of amplification
Effect of ectopic expression of RNaseT2 in SV40 immortalized cell lines
Western blot analysis revealed the expression of the fusion protein in slow-growing clones, but not in fast-growing clones (
. Similar effects were also seen on cloning efficiency and anchorage-independent growth of cells expressing RNaseT2 (Figs 6 and 7). The cloning efficiency of parent CRL-9609 cells, vector transfected clone and a non-expressing transfected clone varied between 52% and 56% as compared to 17-18% observed for RNaseT2 expressing clones of CRL-9609
Superarray analysis of RNaseT2 transfected CSG2 cells
To characterize possible pathways mediating the phenotypic effects of RNaseT2, RNA isolated from parent CSG2 cells and an RNaseT2 expressing clone of CSG2 cells, clone #13, was hybridized to an array of 23 genes representing the Akt pathway. A comparison of the signal intensities between parent cells and gene transfer clone revealed that the transcript levels for most of the genes involved in the Akt pathway, cell proliferation and cell cycle control were reduced in response to the expression of RNaseT2 (Table 1). A significant decrease varying between 2.6-and 10.7-fold was observed for transcripts corresponding to c-jun (10.7-fold), cyclin D1 (4.3-fold), PDK-1 (3.25-fold), matrix metalloproteinase (MMP)-7 (2.8-fold), bcl-2 (2.8-fold) and c-myc (2.6-fold) in CSG2 cells transfected with RNaseT2.
Discussion
RNaseT2 is widely expressed in human tissues. Most immortalized cell lines under express RNAseT2, but at least one ovarian tumour cell line (OVCAR3) showed high levels of its transcript. It is possible that RNaseT2 transcript, in OVCAR3 cells, is either
